Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 26Gynecologic 9Tumor-Agnostic 6Lymphoid 5Genitourinary 5Sarcoma 4Other hematologic neoplasm 4Thoracic 3Endocrine 3Dermatologic 3Other solid neoplasm 2CNS 2Breast 2Head & Neck 1

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific 1Solid Tumors 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × aflibercept × Other solid neoplasm × Clear all
NCT01688960 2015-03-17

Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
48 enrolled
Other solid neoplasm

Solid Tumors

NCT00622414 2014-02-24

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡